Improving healthcare for all

Archeon - A device that provides personalised ventilation of patients in cardiac arrest

With EOlife, Archeon provides first responders and ambulance staff with a connected medical device to facilitate the reanimation of patients suffering a cardiac arrest.

18 Oct 2021

Only 5% of people with out-of-hospital cardiac arrests survive beyond 30 days. With 700,000 cardiac arrests a year in the United States and 50,000 in France, it is still the leading cause of death worldwide.

When developing its connected solution EOlife, Archeon started from the belief that every patient having a cardiac arrest is different. Therefore the ventilation used to resuscitate the patient should be different too. If insufficient oxygen is given, the heart will not restart and the brain will be damaged, in the worst case leading to brain death. If, on the other hand, too much oxygen is given – which happens in 80% of cases – barotrauma occurs. The alveoli in the lungs burst causing potentially fatal pulmonary oedema.

Archeon has therefore designed its solution for use by the first medical teams to arrive on site. This first step in the care of the patient is decisive. However, this is where the problem lies at the moment, due to the lack of any personalised information.

“We wanted to provide a tool for the pre-hospital sector – emergency services, fire brigades, private ambulances, etc…. They don’t know the victim, don’t have his or her medical file and are operating under less than optimal conditions.” Alban De Luca, CEO and Co-founder of Archeon.

EOlife measures the quality of the ventilation via a sensor fitted to the oxygen mask. It calculates the quantities of oxygen given to the patient and the return exhalation. The device has software installed that interprets these measurements and determines the victim’s lung profile in order to adjust the amount of oxygen needed, in real time. This connected solution has been sold in France and in 13 countries in Europe since October 2020.

It is now starting to penetrate the American market, targeting private companies, which are the first on the scene in the event of an out-of-hospital cardiac arrest. This tool could improve the performance of their teams, paid on a fee-for-service basis, and their assessment by insurance companies.

Thanks to the French Healthcare Next Program, Archeon has been put in touch with key actors in this area. Appointments have been made with prescribers and several major distribution networks and institutions, such as the American Heart Association and the American Red Cross.

Member of Medicen Paris Region innovation cluster, partner of the Next French Healthcare Program.

What are you looking for?